Anastrozole and Pitavastatin Interaction

Avoid
Mechanism-based 75% confidence

Anastrozole and Pitavastatin have a potentially harmful interaction with 75% confidence. Both Anastrozole and Pitavastatin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Both compounds affect the heart, so monitoring these systems is recommended.

Compound Profiles

Anastrozole

Aromatase Inhibitor | Estrogen Management

Anastrozole competitively binds to the heme group of the aromatase enzyme (cytochrome P450 19A1), reversibly inhibiting its catalytic activity. Aromatase is responsible for the final step in estrogen biosynthesis, converting testosterone to estradiol and androstenedione to estrone in peripheral tissues including adipose, muscle, liver, and brain.

Half-life: ~40-50 hours Typical dose: 0.25-0.5mg EOD or E3D (estrogen management) pct, anabolic
aromatase androgenicaromatase inhibitorestrogenichepatotoxic
View full profile

Pitavastatin

HMG-CoA Reductase Inhibitor | Low-Interaction Statin

Pitavastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway responsible for cholesterol biosynthesis in the liver. By blocking this enzyme, pitavastatin reduces intracellular cholesterol concentration in hepatocytes, triggering compensatory upregulation of LDL receptor expression on the hepatocyte surface.

Half-life: ~12 hours Typical dose: 1-4 mg/day cardiovascular
aromatase aromatase inhibitorhepatotoxiclipid disruptingteratogenic
View full profile

Combined Organ Load

Gonads
moderate
Heart
moderate
Liver
moderate
Pituitary
low

Shared Safety Flags

2x 2 compounds share the aromatase-inhibitor safety flag (Anastrozole, Pitavastatin). Monitor accordingly.
2x 2 hepatotoxic compounds (Anastrozole, Pitavastatin). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.
2x 2 compounds disrupt lipids (Anastrozole, Pitavastatin). Get lipid panel mid-cycle — consider adding lipid support.
2x 2 compounds share the teratogenic safety flag (Anastrozole, Pitavastatin). Monitor accordingly.

Frequently Asked Questions

Can I take Anastrozole with Pitavastatin?

Combining Anastrozole with Pitavastatin is not recommended. Both Anastrozole and Pitavastatin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is Anastrozole and Pitavastatin safe together?

This combination carries significant risk. Both Anastrozole and Pitavastatin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between Anastrozole and Pitavastatin?

Both Anastrozole and Pitavastatin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 75% confidence and is inferred from pharmacological mechanism analysis.

How should I time Anastrozole and Pitavastatin?

Anastrozole has a half-life of ~40-50 hours and Pitavastatin has a half-life of ~12 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: Anastrozole vs Pitavastatin

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.